Abstract
Felbamate was marketed in the USA in 1993 after undergoing blinded randomized controlled trials as adjunctive therapy for focal seizures and in patients with Lennox–Gastaut syndrome, as well as monotherapy for focal seizures. It appears to have a broad spectrum of efficacy. Felbamate is metabolized in the liver, so that its clearance is increased by enzyme inducers. It has a number of interactions as a result of inhibition of CYP2C19 and induction of CYP3A4. Its adverse effects are mostly referable to the central nervous system and the gastrointestinal system; they improved considerably with simplification of the medication regimen and conversion to monotherapy. Felbamate’s clinical use was markedly reduced by the appearance of serious idiosyncratic toxicity, including aplastic anemia and liver failure. As a result, it is not recommended as initial therapy and its potential benefit must justify the associated risk. Since idiosyncratic adverse effects usually appeared after a latency of several months, a short course of felbamate can be considered in patients with severe epilepsy that has not responded to antiseizure medications.
References
Banfield CR, Zhu GR, Jen JF, Jensen PK, Schumaker RC, Perhach JL, Affrime MB, Glue P. The effect of age on the apparent clearance of felbamate: a retrospective analysis using nonlinear mixed-effects modeling. Ther Drug Monit. 1996;18:19–29.
Binelli S, Canafoglia L, Mamoli D, Avanzini G, Guidolin L, Canger R, Politini L, Sartori I, Tartara A, Perucca E, Giubergia S, Mazzari P, Zagnoni P, Garofalo P, Durisotti C, Ricci S, Manfredi M, Mainardi F, Paladin F, Michelucci R, Tassinari CA, Sasso E, Mancia D, Zaccara G, Mascia V, Marrosu F, Nocerino C, Striano S, Spinelli A, Specchio LM, Russo M, Alagna A, Pisani F, Di Perri R, Raspanti G, Daniele O, Bettini B, Zibetti A, Montanini R, Lunardi G. Felbamate as add-on therapy in adult patients with partial drug-resistant epilepsy. Bollettino Lega Italiana Contro L’Epilessia. 1999;106–107:317–8.
Bourgeois BF. Felbamate in the treatment of partial-onset seizures. Epilepsia. 1994;35(Suppl 5):S58–61.
Bourgeois B, Leppik IE, Sackellares JC, Laxer K, Lesser R, Messenheimer JA, Kramer LD, Kamin M, Rosenberg A. Felbamate: a double-blind controlled trial in patients undergoing presurgical evaluation of partial seizures. Neurology. 1993;43:693–6.
Burdette DE, Sackellares JC. Felbamate pharmacology and use in epilepsy. Clin Neuropharmacol. 1994;17:389–402.
Contin M, Riva R, Albani F, Baruzzi AA. Effect of felbamate on clobazam and its metabolite kinetics in patients with epilepsy. Ther Drug Monit. 1999;21:604–8.
Corradetti R, Pugliese AM. Electrophysiological effects of felbamate. Life Sci. 1998;63:1075–88.
Devinsky O, Faught RE, Wilder BJ, Kanner AM, Kamin M, Kramer LD, Rosenberg A. Efficacy of felbamate monotherapy in patients undergoing presurgical evaluation of partial seizures. Epilepsy Res. 1995;20:241–6.
Faught E, Sachdeo RC, Remler MP, Chayasirisobhon S, Iragui-Madoz VJ, Ramsay RE, Sutula TP, Kanner A, Harner RN, Kuzniecky R, et al. Felbamate monotherapy for partial-onset seizures: an active-control trial. Neurology. 1993;43:688–92.
Felbamate Study Group in Lennox–Gastaut Syndrome. Efficacy of felbamate in childhood epileptic encephalopathy (Lennox–Gastaut syndrome). N Engl J Med. 1993;328:29–33.
Harty TP, Rogawski MA. Felbamate block of recombinant N-methyl-D-aspartate receptors: selectivity for the NR2B subunit. Epilepsy Res. 2000;39:47–55.
Johannessen SI, Landmark CJ. Antiepileptic drug interactions – principles and clinical implications. Curr Neuropharmacol. 2010;8:254–67.
Kelley MT, Walson PD, Cox S, Dusci LJ. Population pharmacokinetics of felbamate in children. Ther Drug Monit. 1997;19:29–36.
Ketter TA, Malow BA, Flamini R, Ko D, White SR, Post RM, Theodore WH. Felbamate monotherapy has stimulant-like effects in patients with epilepsy. Epilepsy Res. 1996;23:129–37.
Kume A, Greenfield LJ Jr, Macdonald RL, Albin RL. Felbamate inhibits [3H]t-butylbicycloorthobenzoate (TBOB) binding and enhances Cl- current at the gamma-aminobutyric AcidA (GABAA) receptor. J Pharmacol Exp Ther. 1996;277:1784–92.
Leppik IE. Felbamate. Epilepsia. 1995;36(Suppl 2):S66–72.
Leppik IE, Dreifuss FE, Pledger GW, Graves NM, Santilli N, Drury I, Tsay JY, Jacobs MP, Bertram E, Cereghino JJ, et al. Felbamate for partial seizures: results of a controlled clinical trial. Neurology. 1991;41:1785–9.
Li LM, Nashef L, Moriarty J, Duncan JS, Sander JW. Felbamate as add-on therapy. Eur Neurol. 1996;36:146–8.
Pellock JM, Faught E, Leppik IE, Shinnar S, Zupanc ML. Felbamate: consensus of current clinical experience. Epilepsy Res. 2006;71:89–101.
Rho JM, Donevan SD, Rogawski MA. Mechanism of action of the anticonvulsant felbamate: opposing effects on N-methyl-D-aspartate and gamma-aminobutyric acid A receptors. Ann Neurol. 1994;35:229–34.
Richens A, Banfield CR, Salfi M, Nomeir A, Lin CC, Jensen P, Affrime MB, Glue P. Single and multiple dose pharmacokinetics of felbamate in the elderly. Br J Clin Pharmacol. 1997;44:129–34.
Sachdeo R, Kramer LD, Rosenberg A, Sachdeo S. Felbamate monotherapy: controlled trial in patients with partial onset seizures. Ann Neurol. 1992;32:386–92.
Shi LL, Bresnahan R, Martin-Mcgill KJ, Dong J, Ni H, Geng J. Felbamate add-on therapy for drug-resistant focal epilepsy. Cochrane Database Syst Rev. 2019;8:CD008295.
Stefani A, Calabresi P, Pisani A, Mercuri NB, Siniscalchi A, Bernardi G. Felbamate inhibits dihydropyridine-sensitive calcium channels in central neurons. J Pharmacol Exp Ther. 1996;277:121–7.
Subramaniam S, Rho JM, Penix L, Donevan SD, Fielding RP, Rogawski MA. Felbamate block of the N-methyl-D-aspartate receptor. J Pharmacol Exp Ther. 1995;273:878–86.
Taylor LA, Mcquade RD, Tice MA. Felbamate, a novel antiepileptic drug, reverses N-methyl-D-aspartate/glycine-stimulated increases in intracellular Ca2+ concentration. Eur J Pharmacol. 1995;289:229–33.
Theodore WH, Raubertas RF, Porter RJ, Nice F, Devinsky O, Reeves P, Bromfield E, Ito B, Balish M. Felbamate: a clinical trial for complex partial seizures. Epilepsia. 1991;32:392–7.
White HS, Wolf HH, Swinyard EA, Skeen GA, Sofia RD. A neuropharmacological evaluation of felbamate as a novel anticonvulsant. Epilepsia. 1992;33:564–72.
White HS, Harmsworth WL, Sofia RD, Wolf HH. Felbamate modulates the strychnine-insensitive glycine receptor. Epilepsy Res. 1995;20:41–8.
White JR, Leppik IE, Beattie JL, Walczak TS, Tran TA, Rarick JO, Vaher P. Long-term use of felbamate: clinical outcomes and effect of age and concomitant antiepileptic drug use on its clearance. Epilepsia. 2009;50:2390–6.
Wilensky AJ, Friel PN, Ojemann LM, Kupferberg HJ, Levy RH. Pharmacokinetics of W-554 (ADD 03055) in epileptic patients. Epilepsia. 1985;26:602–6.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Section Editor information
Rights and permissions
Copyright information
© 2021 Springer Nature Switzerland AG
About this entry
Cite this entry
Abou-Khalil, B. (2021). Anticonvulsant Agents: Felbamate. In: Riederer, P., Laux, G., Nagatsu, T., Le, W., Riederer, C. (eds) NeuroPsychopharmacotherapy. Springer, Cham. https://doi.org/10.1007/978-3-319-56015-1_297-1
Download citation
DOI: https://doi.org/10.1007/978-3-319-56015-1_297-1
Received:
Accepted:
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-56015-1
Online ISBN: 978-3-319-56015-1
eBook Packages: Springer Reference MedicineReference Module Medicine